Predicted Biological Activity of Purchasable Chemical Space

Whereas 400 million distinct compounds are now purchasable within the span of a few weeks, the biological activities of most are unknown. To facilitate access to new chemistry for biology, we have combined the Similarity Ensemble Approach (SEA) with the maximum Tanimoto similarity to the nearest bioactive to predict activity for every commercially available molecule in ZINC. This method, which we label SEA+TC, outperforms both SEA and a naïve-Bayesian classifier via predictive performance on a 5-fold cross-validation of ChEMBL’s bioactivity data set (version 21). Using this method, predictions for over 40% of compounds (>160 million) have either high significance (pSEA ≥ 40), high similarity (ECFP4MaxTc ≥ 0.4), or both, for one or more of 1382 targets well described by ligands in the literature. Using a further 1347 less-well-described targets, we predict activities for an additional 11 million compounds. To gauge whether these predictions are sensible, we investigate 75 predictions for 50 drugs lacking a binding affinity annotation in ChEMBL. The 535 million predictions for over 171 million compounds at 2629 targets are linked to purchasing information and evidence to support each prediction and are freely available via https://zinc15.docking.org and https://files.docking.org.

[1]  Leslie Wilson,et al.  Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype , 2015, Cancer Chemotherapy and Pharmacology.

[2]  Yukiko Muraki,et al.  Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  Kenneth M Merz,et al.  The Ecstasy and Agony of Assay Interference Compounds. , 2017, ACS medicinal chemistry letters.

[4]  Armin Ruf,et al.  Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors , 2012, ChemMedChem.

[5]  Lirong Wang,et al.  TargetHunter: An In Silico Target Identification Tool for Predicting Therapeutic Potential of Small Organic Molecules Based on Chemogenomic Database , 2013, The AAPS Journal.

[6]  Christian Buning,et al.  Small Macrocycles As Highly Active Integrin α2β1 Antagonists. , 2014, ACS medicinal chemistry letters.

[7]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[8]  Grzegorz Godlewski,et al.  Atypical cardiostimulant β‐adrenoceptor in the rat heart: stereoselective antagonism by bupranolol but lack of effect by some bupranolol analogues , 2003, British journal of pharmacology.

[9]  H. Nishino,et al.  Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. , 1989, Japanese journal of pharmacology.

[10]  B Salafsky,et al.  Structure-affinity relationships between several new benzodiazepine derivatives and 3H-diazepam receptor sites. , 1984, Japanese journal of pharmacology.

[11]  J. Mozrzymas,et al.  Comparison of kinetic and pharmacological profiles of recombinant α1γ2L and α1β2γ2L GABAA receptors - A clue to the role of intersubunit interactions. , 2016, European journal of pharmacology.

[12]  Scott P. Brown,et al.  A unified, probabilistic framework for structure- and ligand-based virtual screening. , 2011, Journal of medicinal chemistry.

[13]  Hikaru Tanaka,et al.  Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. , 2006, Cardiovascular drug reviews.

[14]  Michael Paul Deninno Discovery of Triazolopyrimidine-Based PDE8B Inhibitors: Exceptionally Ligand-Efficient and Lipophilic Ligand-Efficient Compounds for the Treatment of Diabetes. , 2013 .

[15]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[16]  D J Greenblatt,et al.  Pharmacology of benzodiazepine hypnotics. , 1992, The Journal of clinical psychiatry.

[17]  H. DeLuca,et al.  Isolation and identification of 25-hydroxycholecalciferol from human plasma. , 1972, Archives of internal medicine.

[18]  S. Mathews,et al.  Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. , 1994, Hypertension.

[19]  G. R. Brown,et al.  Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. , 1995, Journal of medicinal chemistry.

[20]  Tao Huang,et al.  MOST: most-similar ligand based approach to target prediction , 2017, BMC Bioinformatics.

[21]  Artem Cherkasov,et al.  Optimization and structure-activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents. , 2012, Bioorganic & medicinal chemistry.

[22]  Alexandra Aubry,et al.  Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. , 2009, The Journal of antimicrobial chemotherapy.

[23]  Yurii S Moroz,et al.  Sulfonyl fluorides as alternative to sulfonyl chlorides in parallel synthesis of aliphatic sulfonamides. , 2014, ACS combinatorial science.

[24]  Philip A. MacFaul,et al.  Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors , 2013 .

[25]  P. Bork,et al.  Drug discovery in the age of systems biology: the rise of computational approaches for data integration. , 2012, Current opinion in biotechnology.

[26]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[27]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[28]  Makoto Araie,et al.  Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. , 2006, Cardiovascular drug reviews.

[29]  M. Williams,et al.  Effect of Fiduxosin, an Antagonist Selective for α1A- and α1D-Adrenoceptors, on Intraurethral and Arterial Pressure Responses in Conscious Dogs , 2002 .

[30]  Andreas Bender,et al.  In Silico Target Predictions: Defining a Benchmarking Data Set and Comparison of Performance of the Multiclass Naïve Bayes and Parzen-Rosenblatt Window , 2013, J. Chem. Inf. Model..

[31]  T. Kameyama,et al.  The interaction of eptazocine, a novel analgesic, with opioid receptors. , 1985, Research communications in chemical pathology and pharmacology.

[32]  S Seeber,et al.  A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  G. Schneider,et al.  Review : Macromolecular target prediction by self-organizing feature maps , 2016 .

[34]  Makoto Aihara,et al.  The effects of prostaglandin analogues on intracellular Ca2+ in ciliary arteries of wild-type and prostanoid receptor-deficient mice. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[35]  Ricardo Macarron,et al.  Chemical libraries: How dark is HTS dark matter? , 2015, Nature chemical biology.

[36]  Thierry Langer,et al.  High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening , 2007, J. Comput. Aided Mol. Des..

[37]  Yixin Chen,et al.  Implementation of multiple-instance learning in drug activity prediction , 2012, BMC Bioinformatics.

[38]  Minoru Yamamoto,et al.  Effects of a new TRH analogue, YM-14673 on the central nervous system , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[39]  K. Chergui,et al.  Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. , 1997, The Journal of pharmacology and experimental therapeutics.

[40]  B C McGorum,et al.  Bronchodilator activity of the selective muscarinic antagonist revatropate in horses with heaves. , 2013, Veterinary journal.

[41]  B. Holmes,et al.  Meptazinol , 1983, The Lancet.

[42]  Anne Mai Wassermann,et al.  Dark chemical matter as a promising starting point for drug lead discovery. , 2015, Nature chemical biology.

[43]  Wendy Shelly,et al.  Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings , 2008, Obstetrical & gynecological survey.

[44]  S Tsukagoshi [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]. , 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

[45]  Pierre Baldi,et al.  One- to Four-Dimensional Kernels for Virtual Screening and the Prediction of Physical, Chemical, and Biological Properties. , 2007 .

[46]  G. Rolinson,et al.  Flucloxacillin, a New Isoxazolyl Penicillin, Compared with Oxacillin, Cloxacillin, and Dicloxacillin , 1970, British medical journal.

[47]  Thierry Langer,et al.  Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..

[48]  Natasha Bray Lead identification: Shedding light on dark chemical matter , 2015, Nature Reviews Drug Discovery.

[49]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[50]  Haruko Masumiya,et al.  Inhibition of T-Type and L-Type Ca2+ Currents by Aranidipine, a Novel Dihydropyridine Ca2+ Antagonist , 2000, Pharmacology.

[51]  Leah Rider,et al.  Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[52]  M J Gorrill,et al.  Pharmacology of estrogens and estrogen-induced effects on nonreproductive organs and systems. , 1986, The Journal of reproductive medicine.

[53]  J R Gibson,et al.  Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. , 1991, Journal of the American Academy of Dermatology.

[54]  Jun Xu,et al.  Toward automated biochemotype annotation for large compound libraries , 2006, Molecular Diversity.

[55]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[56]  Richard J Whitby,et al.  Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2). , 2011, Journal of medicinal chemistry.

[57]  Yong-Yeol Ahn,et al.  Optimizing drug–target interaction prediction based on random walk on heterogeneous networks , 2015, Journal of Cheminformatics.

[58]  R. N. Brogden,et al.  Hexoprenaline: A Review of its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Asthma , 1977, Drugs.

[59]  Jérôme Hert,et al.  Quantifying Biogenic Bias in Screening Libraries , 2009, Nature chemical biology.

[60]  D. Kass,et al.  Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors. , 2012, The American journal of cardiology.

[61]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[62]  D. Attwood,et al.  Aggregation of antiacetylcholine drugs in aqueous solution: monomer concentrations in non‐micellar drug systems , 1976, The Journal of pharmacy and pharmacology.

[63]  Anne Hersey,et al.  Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain. , 2010, Bioorganic & medicinal chemistry letters.

[64]  Thomas M Frimurer,et al.  6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode. , 2005, Journal of medicinal chemistry.

[65]  R. Pieters,et al.  Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1. , 2013, Journal of medicinal chemistry.

[66]  Antti Poso,et al.  Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. , 2006, Journal of medicinal chemistry.

[67]  Nobuyoshi Sugaya,et al.  Training Based on Ligand Efficiency Improves Prediction of Bioactivities of Ligands and Drug Target Proteins in a Machine Learning Approach , 2013, J. Chem. Inf. Model..

[68]  Yurii S. Moroz,et al.  One-Pot Parallel Synthesis of Alkyl Sulfides, Sulfoxides, and Sulfones. , 2015, ACS combinatorial science.

[69]  Eiichi Fuse,et al.  Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives. , 2008, Bioorganic & medicinal chemistry letters.

[70]  Michael J. Keiser,et al.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.

[71]  A. Orjales,et al.  Preclinical Pharmacology of Bilastine, a New Selective Histamine H1 Receptor Antagonist , 2005, Drugs in R&D.

[72]  Anne M. V. Brooks,et al.  Ocular β-Blockers in Glaucoma Management , 1992 .

[73]  Pavel K Mykhailiuk,et al.  Copper-Catalyzed O-Difluoromethylation of Functionalized Aliphatic Alcohols: Access to Complex Organic Molecules with an OCF2H Group. , 2016, The Journal of organic chemistry.

[74]  Yurii S Moroz,et al.  Expanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles. , 2016, ACS combinatorial science.

[75]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[76]  Maria F. Sassano,et al.  In Silico Molecular Comparisons of C. elegans and Mammalian Pharmacology Identify Distinct Targets That Regulate Feeding , 2013, PLoS biology.

[77]  Simon,et al.  A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Hypertension and Angina Pectoris , 2012 .

[78]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[79]  J. Irwin,et al.  Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.

[80]  T. Hofmann,et al.  Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF‐κB‐dependent transcription , 1998, FEBS letters.

[81]  E Solito,et al.  Anti-inflammatory mechanism of alminoprofen: action on the phospholipid metabolism pathway. , 1999, Biochemical pharmacology.

[82]  C B Christensen,et al.  The opioid receptor binding profiles of ketobemidone and morphine. , 1993, Pharmacology & toxicology.

[83]  F. Dilworth,et al.  The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. , 1997, Endocrinology.

[84]  Isidro Cortes-Ciriano,et al.  Chemically Aware Model Builder (camb): an R package for property and bioactivity modelling of small molecules , 2015, Journal of Cheminformatics.

[85]  R. Glen,et al.  Diversity Selection of Compounds Based on ‘Protein Affinity Fingerprints’ Improves Sampling of Bioactive Chemical Space , 2013, Chemical biology & drug design.

[86]  J Mørland,et al.  Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. , 1995, British journal of clinical pharmacology.

[87]  J. Irwin,et al.  Identifying mechanism-of-action targets for drugs and probes , 2012, Proceedings of the National Academy of Sciences.

[88]  E M Sorkin,et al.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. , 1988, Drugs.

[89]  P. Skolnick,et al.  Triple uptake inhibitors: therapeutic potential in depression and beyond , 2007, Expert opinion on investigational drugs.

[90]  J W Oliver,et al.  The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. , 2003, Veterinary ophthalmology.

[91]  Jun Inui,et al.  β-adrenoceptor blocking and electrophysiological effects of bufetolol in the guinea pig atria , 1977 .

[92]  Yurii S Moroz,et al.  2,2,2-Trifluoroethyl Chlorooxoacetate--Universal Reagent for One-Pot Parallel Synthesis of N(1)-Aryl-N(2)-alkyl-Substituted Oxamides. , 2015, ACS combinatorial science.

[93]  Valerie J Gillet,et al.  New directions in library design and analysis. , 2008, Current opinion in chemical biology.

[94]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[95]  G Castañeda-Hernández,et al.  Mechanisms underlying the anti‐inflammatory activity and gastric safety of acemetacin , 2007, British journal of pharmacology.

[96]  R. Goldberg,et al.  Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. , 1988, Drugs.

[97]  Yurii S. Moroz,et al.  Bis(2,2,2-trifluoroethyl) carbonate as a condensing agent in one-pot parallel synthesis of unsymmetrical aliphatic ureas. , 2014, ACS combinatorial science.

[98]  Subhash C Basak Mathematical descriptors for the prediction of property, bioactivity, and toxicity of chemicals from their structure: a chemical-cum-biochemical approach. , 2013, Current computer-aided drug design.

[99]  G Houin,et al.  Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man. , 1984, International journal of clinical pharmacology research.

[100]  S. Zozulya,et al.  Design, synthesis, and characterization of SO2-containing azabicyclo[3.n.1]alkanes: promising building blocks for drug discovery. , 2015, Organic letters.

[101]  Yurii S Moroz,et al.  A one-pot parallel reductive amination of aldehydes with heteroaromatic amines. , 2014, ACS combinatorial science.

[102]  Murali Gopalakrishnan,et al.  Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain. , 2009, Biochemical pharmacology.

[103]  Peter Svensson,et al.  Influence of Polymorphisms in the HTR3A and HTR3B Genes on Experimental Pain and the Effect of the 5-HT3 Antagonist Granisetron , 2016, PloS one.

[104]  Prasenjit Mukherjee,et al.  Performance of Dark Chemical Matter in High Throughput Screening. , 2016, Journal of medicinal chemistry.

[105]  Jean-Christophe Cassel,et al.  Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats , 2001, Pharmacology Biochemistry and Behavior.

[106]  Sung Gu Kang,et al.  Udenafil: efficacy and tolerability in the management of erectile dysfunction , 2013, Therapeutic advances in urology.

[107]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[108]  Yongdong Zhang,et al.  Drug-target interaction prediction: databases, web servers and computational models , 2016, Briefings Bioinform..

[109]  Péter Hári,et al.  Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching , 2013, J. Chem. Inf. Model..

[110]  Bryan L. Roth,et al.  Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.

[111]  Lewis R. Vidler,et al.  Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B , 2015, Journal of medicinal chemistry.

[112]  David J. Wild,et al.  Fast rule-based bioactivity prediction using associative classification mining , 2012, Journal of Cheminformatics.

[113]  Ulrich Klotz,et al.  Interaction Potential of Lercanidipine, a New Vasoselective Dihydropyridine Calcium Antagonist , 2002, Arzneimittelforschung.

[114]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[115]  Pierre Baldi,et al.  One- to Four-Dimensional Kernels for Virtual Screening and the Prediction of Physical, Chemical, and Biological Properties , 2007, J. Chem. Inf. Model..

[116]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[117]  A. Markham,et al.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. , 1996, Drugs.

[118]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[119]  H Imamura,et al.  Beta-adrenoceptor blocking and electrophysiological effects of bufetolol in the guinea pig atria. , 1977, European journal of pharmacology.

[120]  R P GUSTAVO [Anti-gonadotropic action of possipione]. , 1958, Quaderni di clinica ostetrica e ginecologica.

[121]  Petra Schneider,et al.  Scoring of de novo Designed Chemical Entities by Macromolecular Target Prediction , 2017, Molecular informatics.

[122]  Michael Williams,et al.  Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. , 2002, The Journal of pharmacology and experimental therapeutics.

[123]  Stefan Vasile,et al.  Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro. , 2012, Journal of medicinal chemistry.

[124]  J. Palacios,et al.  Axonal transport of beta-adrenergic receptors. Antero- and retrogradely transported receptors differ in agonist affinity and nucleotide sensitivity. , 1983, Molecular pharmacology.

[125]  Adrià Cereto-Massagué,et al.  Tools for in silico target fishing. , 2015, Methods.